Samuel Agresta, MD, MPH & TM
Samuel Agresta, MD, MPH & TM, joined Foghorn Therapeutics in 2019 as chief medical officer. He brings over a decade of clinical development experience with global development and regulatory expertise in both solid and hematologic cancers.
Prior to joining Foghorn, Sam was the chief medical officer at Infinity Pharmaceuticals. During his career, Sam spent 8 years at Agios Pharmaceuticals, where he was responsible for the development and approvals of TIBSOVO® and IDHIFA® for patients with IDH1 and IDH2 mutation positive acute myeloid leukemia. Sam has also held positions at Merrimack and Genentech. While he was at Genentech, he played a role in the global development of KADCYLA®, which is approved for HER2 positive breast cancer. Sam was trained in medical oncology at the University of South Florida’s Moffitt Cancer Center and stayed on as an associate medical director in the Sarcoma Department.
Sam is a member of Infinity’s Board of Directors. He received his medical degree from Tulane University School of Medicine as well as a Master in Public Health from Tulane University School of Health and Tropical Medicine.